MarketResearchReport2021

Bone Metastasis Market The increasing prevalence of breast cancer, growing geriatric population, rising healthcare expenditures, and increasing R&D expenses by the key players are estimated to drive the market growth during the forecast period. The Bone Metastasis Market is expected to reach USD 17.34 Billion by 2030 at 9.30% CAGR during the forecast period 2022-2030 Bone metastasis is a condition that occurs when cancerous cells from a non-bone site travel, i.e. metastasize, to bones. The spine, particularly the lower spine, the pelvis, and the thighs, are the most common sites for bone metastases. Bone metastasis can cause urinary and bowel incontinence, due to it being located quite close to both the urinary bladder and the rectal column, as well as hypercalcemia. While all cancers can manifest in this way, breast and prostate cancers are the likeliest sources of bone metastasis – 65-75% of patients suffering from breast or prostate cancers experience bone metastasis. The

  Bone Metastasis  Market The increasing prevalence of breast cancer, growing geriatric population, rising healthcare expenditures, and increasing R&D expenses by the key players are estimated to drive the market growth during the forecast period. The  Bone Metastasis Market  is expected to reach USD 17.34 Billion by 2030 at 9.30% CAGR during the forecast period 2022-2030 However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period. Major Key Players: The key players in the global bone metastasis market are F. Hoffmann-La Roche Ltd (Switzerland) Bayer AG (Germany), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc. (England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others. Segment Analysis The global bone metastasis